Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

Activating NRAS mutations are found in 15-20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g. NRAS mutations) correlate with benefit from immune therapy in melanoma. We identified 229 melanoma patients treated w...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Immunol Res
Päätekijät: Johnson, Douglas B., Lovly, Christine M., Flavin, Marisa, Panageas, Katherine S., Ayers, Gregory D., Zhao, Zhiguo, Iams, Wade T., Colgan, Marta, DeNoble, Sarah, Terry, Charles R., Berry, Elizabeth G., Iafrate, A. John, Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351797/
https://ncbi.nlm.nih.gov/pubmed/25736262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-14-0207
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia